We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

55 hedge funds and large institutions have $53.9M invested in Galectin Therapeutics in 2014 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 15 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

550% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 4

328% more capital invested

Capital invested by funds: $12.6M → $53.9M (+$41.3M)

200% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 5

67% more funds holding

Funds holding: 33 → 55 (+22)

61% less call options, than puts

Call options by funds: $3.35M | Put options by funds: $8.65M

Holders
55
Holders Change
+22
Holders Change %
+66.67%
% of All Funds
1.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
15
Reduced
5
Closed
4
Calls
$3.35M
Puts
$8.65M
Net Calls
-$5.3M
Net Calls Change
-$4.74M

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$5.69M
2
CAM
Cormorant Asset Management
Massachusetts
+$4.96M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.91M
4
MP
Mangrove Partners
Connecticut
+$2.85M
5
EI
EAM Investors
California
+$2.31M

Top Sellers

Rank Fund Capital Flow
1
CCA
Catalyst Capital Advisors
New York
-$1.65M
2
Neuberger Berman Group
Neuberger Berman Group
New York
-$673K
3
DADC
D.A. Davidson & Co
Montana
-$602K
4
WAM
Wolverine Asset Management
Illinois
-$447K
5
LOM
Loeb Offshore Management
New York
-$90K
Name Holding Trade Value Shares
Change 		Change in
Stake
California Public Employees Retirement System
26
California Public Employees Retirement System
California
$282K – – –
CCI
27
Columbus Circle Investors
$261K +$242K +17,026 New
Commonwealth Equity Services
28
Commonwealth Equity Services
Massachusetts
$237K +$221K +15,496 New
FIM
29
Freedom Investment Management
Connecticut
$232K +$31.4K +2,203 +17%
TAM
30
Tocqueville Asset Management
New York
$207K +$192K +13,500 New
Jane Street
31
Jane Street
New York
$204K +$190K +13,351 New
JP Morgan Chase
32
JP Morgan Chase
New York
$165K +$153K +10,745 New
GC
33
Guggenheim Capital
Illinois
$161K +$150K +10,523 New
Wells Fargo
34
Wells Fargo
California
$132K +$92.8K +6,516 +307%
Creative Planning
35
Creative Planning
Kansas
$117K – – –
Bank of America
36
Bank of America
North Carolina
$108K +$71.5K +5,022 +246%
BIT
37
BlackRock Institutional Trust
California
$89K +$82.5K +5,793 New
Goldman Sachs
38
Goldman Sachs
New York
$79K +$73.3K +5,144 New
BG
39
BlackRock Group
United Kingdom
$73K +$67.3K +4,727 New
Deutsche Bank
40
Deutsche Bank
Germany
$48K +$44.8K +3,146 New
QT
41
Quantbot Technologies
New York
$30K +$28.5K +2,000 New
First Manhattan
42
First Manhattan
New York
$25K – – –
TC
43
TradeLink Capital
Illinois
$18K +$17.1K +1,200 New
OIA
44
Optimum Investment Advisors
Illinois
$13K +$1.37K +96 +13%
LTFS
45
Ladenburg Thalmann Financial Services
Florida
$8K – – –
Citigroup
46
Citigroup
New York
$7K +$2.78K +195 +83%
AllianceBernstein
47
AllianceBernstein
Tennessee
$6K +$2.85K +200 +94%
RIA
48
Regal Investment Advisors
Michigan
$5K +$4.27K +300 New
TWA
49
TCI Wealth Advisors
Arizona
$5K +$4.27K +300 New
TRCT
50
Tower Research Capital (TRC)
New York
$2K -$52K -3,654 -97%
1
2
3

GALT Hedge Fund Activity: Q1 2014 in Review

55 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2014, worth a combined $53.9M — up 328% from $12.6M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new GALT positions and 4 closed out — a net gain of 22 holders — while 15 added to existing stakes and 5 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $5.69M. The largest seller was Catalyst Capital Advisors, exiting entirely with an estimated $1.65M sold.

  • 55 institutional investors held Galectin Therapeutics (GALT) as of Q1 2014, up from 33 in Q4 2013.
  • Funds reported $53.9M of Galectin Therapeutics stock for Q1 2014, up 328% quarter-over-quarter.
  • 26 funds opened new Galectin Therapeutics positions in Q1 2014 and 4 closed out, a net change of +22 holders.
  • The largest Galectin Therapeutics buyer in Q1 2014 was Baker Bros. Advisors, an estimated $5.69M added.
  • The largest Galectin Therapeutics seller in Q1 2014 was Catalyst Capital Advisors, an estimated $1.65M sold.

Based on aggregated 13F filings for Q1 2014.